Clinical trials: Mild Dyslipidemia
Hypertriglyceridemia
Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides
The investigators will conduct a randomized clinical trial to evaluate the efficacy of Lovaza (formerly known as Omacor) in reducing triglyceride levels in youth ages 10-19 years old whose baseline triglycerides range from 150…
- Trial name
- NCT00672633
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Boston Children's Hospital
Hypercholesterolemia
LDL-cholesterol Lowering Effect of a New Dietary Supplement
The aim of this study was to assess the lipid-lowering activity and safety of a dietary supplement containing monacolin K, L-arginine, coenzyme Q10 and ascorbic acid (vitamin C).
- Trial name
- NCT03425630
- Testing
- Argicolina, Normolip
- Volunteers
- 20 people
- Sponsor
- Ispharm srl
Dyslipidemias
Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia
The purpose of this study is to investigate whether astaxanthin supplementation can impact triglyceride plasmatic concentrations in volunteers presenting mild dyslipidemia.
- Trial name
- LLAX (NCT02343497)
- Testing
- Astaxanthin
- Where
- France
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ajinomoto Foods Europe SAS
Hypercholesterolemia
Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Spain)
The purpose of this study is to investigate the cholesterol lowering effect of a drinkable low fat fermented milk enriched with plant sterol after 3 and 6 weeks in mildly hypercholesterolemic subjects treated or not by statins.
- Trial name
- NCT01600820
- Testing
- 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit, 2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit, 3- Low fat drinkable fermented dairy product without plant sterols(control)
- Where
- Spain
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Danone Spain
Chronic Smokers, Hyperlipidemia
Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate…
- Trial name
- NCT02100202
- Testing
- BioTurmin (Curcuma longa rhizomes extract), BioTurmin-WD (Water dispersible curcuminoids), MaQxan (Tagetes erecta flower extract)
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Olive Lifesciences Pvt Ltd
Hyperlipidemia
The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL)
Antioxidants are potent scavengers of free radicals and serve as inhibitors of neoplastic processes. A large number of synthetic and natural antioxidants are known to induce beneficial effects on human health and disease…
- Trial name
- GSE (NCT00713167)
- Testing
- Grape Seed Extract (Vitagrape)
- Where
- 2 sites in Iran
- Volunteers
- 55 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Hypercholesterolemia
Safety Study of Bile Acid to Treat Hypercholesteremia
Preclinical data support the hypothesis that the administration of AHRO-001 reduces LDL cholesterol levels, improves HDL function, and finally, decreases atheromatous plaque burden.
- Trial name
- NCT01931241
- Testing
- AHRO-001
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AtheroNova Inc.
Hypercholesterolemia
Effects of Black Tea Intake on Serum Lipids
A diet-controlled clinical trial which attempts to provide estimates of the effect of black tea consumption on serum lipids under tightly controlled conditions, including a controlled diet.
- Trial name
- NCT01882283
- Testing
- Tea Treatment Group
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Dyslipidemias
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take…
- Trial name
- VINCENT (NCT06496243)
- Testing
- obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- NewAmsterdam Pharma
Dyslipidaemias
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low…
- Trial name
- NCT00169559
- Testing
- GW590735, fenofibrate
- Where
- 50 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Healthy, Mild Hypercholesterolemia
A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink
The purpose of this study is to investigate the safety of consumption of three times the standard dose of a yoghurt drink enriched with 1600 mg of plant sterols.
- Trial name
- NCT01629888
- Testing
- 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols)., 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Danone Japan
Hypertriglyceridemia
TRIal For Efficacy of Capre on hyperTriglyceridemiA
The purpose of this study is to determine whether CaPre(TM), given at doses 1.0g or 2.0g for 12 weeks, has an effect on fasting plasma triglycerides in patients with mild to high hypertriglyceridemia as compared to a placebo.
- Trial name
- TRIFECTA (NCT01455844)
- Testing
- CaPre (TM)
- Where
- 38 sites in Canada
- Volunteers
- 387 people
- Sponsor
- Grace Therapeutics Inc.
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10582 following single and multiple dose administration to healthy subjects and subjects with Mildly Elevated LDL-C.
- Trial name
- NCT07777003
- Testing
- HS-10582
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hyperlipidemias, Hypertriglyceridemia
Barberry and Cardiometabolic Risk Factors in Individuals With Hypertriglyceridemia
Barberry is a well-documented medicinal plant that is utilized as a feed additive in a variety of food cultures. Barberry is a rich source of antioxidants, minerals, phenolic compounds, and flavonoids.
- Trial name
- NCT06483932
- Testing
- Dried barberry, Low-calorie diet
- Where
- Iran
- Volunteers
- 56 people
- Sponsor
- Shahid Beheshti University
Hyperlipemia
Effect of Consumption of Bagel Without Palm Oil on Postprandial Lipidemia
Postprandial lipemia produced by fat intake is a major risk factor for the development of cardiovascular diseases (CVD), the most important cause of disease and death in the Western world.
- Trial name
- PALMFREE (NCT03950752)
- Testing
- Optimized Bagel, Conventional Bagel
- Where
- Spain
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Technological Centre of Nutrition and Health, Spain
Hypercholesterolemia
A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia
The primary objective of this study is to assess the effect of AVE5530 on LDL-C levels over a period of 4 weeks. The secondary objectives are to assess the effects of AVE5530 on other lipid plasma levels and the safety and…
- Trial name
- NCT00440154
- Testing
- AVE5530, ezetimibe
- Where
- 6 sites in Chile, Hungary and 4 more
- Volunteers
- 206 people
- Sponsor
- Sanofi
Hyperlipidemia, Hypertension
Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients
This is a single-center, randomized, double-blind, placebo-controlled, cross-over study. Subjects who meet the inclusion/exclusion criteria will be randomly and alternatively assigned to receive Shanzha fruit drink or placebo…
- Trial name
- NCT04672278
- Where
- Hong Kong
- Volunteers
- 72 people
- Sponsor
- Chinese University of Hong Kong
Cholesterol, Hypercholesterolaemia
Efficacy of Lactobacillus Mucosae DPC6426 on Blood-lipids
Cardiovascular disease (CVD) is the leading cause of death and morbidity in the EU. Among the recommendations to avoid heart disease is the maintenance of normal blood cholesterol levels, by ingesting a cardioprotective diet and…
- Trial name
- NCT07519967
- Testing
- Lactobacillus mucosae DPC6426
- Where
- Ireland
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University College Cork
Dementia, Alzheimer Disease
Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias
The investigators aim to study the effects of a 24-week remote-based resistance exercise training program on cardiovascular disease risk factors, cognitive function, and quality of life in older adults living with mild cognitive…
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Lewy Body Disease
- Trial name
- NCT05004558
- Testing
- Remote-based Resistance Exercise Training
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Drexel University
Dyslipidaemias, Dyslipidaemia
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
The purpose of this clinical research study is to compare up to 3 doses of an investigational drug GW501516 to placebo (an inactive pill that looks like GW501516) to see if it is safe, well tolerated and effective in improving…
- Trial name
- NCT00158899
- Testing
- GW501516 oral tablets
- Where
- 64 sites in Belgium, Denmark and 9 more
- Volunteers
- 424 people
- Sponsor
- GlaxoSmithKline